Vanderbilt spinout Appello has been backed by Deerfield Management, which recently launched a $65m commercialisation partnership with the university.
Appello Pharmaceuticals, a US-based neurodegenerative disease therapy spinout from Vanderbilt University, closed a $10.5m series A round yesterday co-led by healthcare-focused investment firm Deerfield Management and Mountain Group Partners.
Deerfield and Vanderbilt have launched a $65m commercialisation fund focused on pharmaceutical spinouts, though Appello did not explicitly state this was the source of Deerfield’s commitment.
Appello is developing a treatment for Parkinson’s disease, a progressive brain disorder caused by the death of dopamine-producing nerve cells in the brain’s substantia…
